Could a sticky patch replace the dreaded sugar drink test for new moms?
NCT ID NCT07332416
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study is testing whether a continuous glucose monitor (CGM) worn on the arm for 14 days can replace the standard oral glucose tolerance test (OGTT) for women who had gestational diabetes. Many women find the OGTT burdensome and skip it, missing a chance to catch lingering blood sugar problems. The study will enroll 1,300 women 12-16 weeks after childbirth to see how many actually use and return the CGM sensor.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- continuous glucose monitor (Freestyle LibrePro)
- What this could lead to
- If successful, this could offer a simpler, more comfortable way to screen for diabetes after pregnancy, potentially improving follow-up care and long-term health.
- What could go wrong
- This is a pilot study focused on whether women will use the device, not on health outcomes. The CGM may not be as accurate as the standard test, and results may not apply to non-English speakers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 12-16 weeks postpartum * Gestational diabetes Mellitus (GDM) diagnosis in most recent pregnancy * Oral Glucose Tolerance Test (OGTT) order placed in the medical record Exclusion Criteria: * Pre-gestational diabetes * Non-English language
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gestational diabetes are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Wearable sensors in early pregnancy may reveal hidden diabetes risk
- Could a simple blood test predict newborn risks in diabetic pregnancies?
- Wearable sensor may replace the dreaded glucose drink test for gestational diabetes
- Wearable tech could stop Post-Pregnancy diabetes in its tracks
- Could oxidative stress be the hidden culprit behind blood vessel damage after gestational diabetes?
- Blood vessel damage after gestational diabetes: is a rogue enzyme to blame?